Bryan Johnson Pursues CAR-T Therapy After Autoimmune Gastritis Diagnosis at 48
Updated
Updated · Outside · Jul 8
Bryan Johnson Pursues CAR-T Therapy After Autoimmune Gastritis Diagnosis at 48
3 articles · Updated · Outside · Jul 8
Summary
CAR-T therapy is the experimental option Johnson says his team is now exploring after his autoimmune gastritis diagnosis, a condition that destroys acid-producing stomach cells and blocks iron absorption.
4% of people worldwide may have the disease, but experts say it is often missed because early signs can be limited to low ferritin while hemoglobin and hematocrit remain normal; confirmation requires endoscopy with biopsies.
13 times higher neuroendocrine tumor risk is one reason treatment is largely limited to iron replacement and cancer surveillance, with no established cure and only early-stage evidence for CAR-T in this condition.
Johnson's case has also highlighted screening gaps: he said he was overdue for a colonoscopy at 48, even though U.S. guidelines lowered the recommended starting age to 45 in 2021.
Experts say the diagnosis underscores both the limits of intensive longevity regimens and the need for more routine biopsies in patients with persistent iron deficiency.